Research location
Leesburg
Virginia, United States
Advertisement
Research activity in Leesburg
Virginia, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 40 trials and 40 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Leesburg
40 linked trials · page 1 of 1A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213 · 2026-07-06 · 1 site observation
RECRUITING
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerNCT07213674 · 2025-11-28 · 1 site observation
RECRUITING
E-Mindfulness Approaches for Living After Breast CancerNCT06748222 · 2025-06-27 · 1 site observation
RECRUITING
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsNCT06772623 · 2025-03-06 · 1 site observation
RECRUITING
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialNCT06500481 · 2025-03-04 · 1 site observation
RECRUITING
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsNCT06357533 · 2024-04-11 · 1 site observation
RECRUITING
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7NCT04613596 · 2020-12-02 · 1 site observation
RECRUITING
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsNCT05896189 · 2024-02-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Buen Provecho!: A Virtual Family-Based Intervention to Promote HealthNCT05419557 · 2022-08-17 · 1 site observation
COMPLETED
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)NCT04622007 · 2021-06-02 · 1 site observation
UNKNOWN
Breast Cancer Index (BCI) RegistryNCT04875351 · 2021-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C MutationNCT04685135 · 2021-02-23 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast CancerNCT04539938 · 2020-12-01 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%NCT04435626 · 2020-09-14 · 1 site observation
COMPLETED
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerNCT03975647 · 2019-10-02 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate CancerNCT03871816 · 2019-04-22 · 1 site observation
COMPLETED
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.NCT03619213 · 2018-08-27 · 1 site observation
COMPLETED
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast CancerNCT03414970 · 2018-03-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or PlaceboNCT03281954 · 2017-12-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)NCT02574455 · 2017-11-07 · 1 site observation
COMPLETED
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection FractionNCT02929329 · 2017-01-06 · 1 site observation
COMPLETED
Palbociclib in Real World PracticeNCT03280303 · 2017-01-04 · 1 site observation
COMPLETED
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor TherapyNCT02756364 · 2016-07-28 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast CancerNCT02481050 · 2015-06-16 · 1 site observation
COMPLETED
A Study Of PF-06647020 For Adult Patients With Advanced Solid TumorsNCT02222922 · 2014-10-17 · 1 site observation
COMPLETED
Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance StudyNCT02294331 · 2014-08-01 · 1 site observation
COMPLETED
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung CancerNCT02119650 · 2014-02-11 · 1 site observation
TERMINATED
Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)NCT01942135 · 2013-09-26 · 1 site observation
COMPLETED
A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)NCT01922037 · 2013-06-19 · 1 site observation
COMPLETED
The Product Surveillance Registry REVERSE Post Approval StudyNCT01660035 · 2012-04-01 · 1 site observation
COMPLETED
Model 4296 Left Ventricular (LV) Lead Chronic Performance StudyNCT01361672 · 2011-05-01 · 1 site observation
COMPLETED
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung CancerNCT01244191 · 2011-01-11 · 1 site observation
TERMINATED
Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung CancerNCT01104155 · 2010-02-22 · 1 site observation
COMPLETED
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab AloneNCT00968968 · 2010-01-20 · 1 site observation
TERMINATED
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerNCT00887536 · 2009-05-01 · 1 site observation
COMPLETED
Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast CancerNCT00721409 · 2008-09-15 · 1 site observation
COMPLETED
Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma HistologyNCT00596830 · 2008-04-01 · 1 site observation
TERMINATED
Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic RetinopathyNCT00445003 · 2007-03-01 · 1 site observation
COMPLETED
A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast CancerNCT00373256 · 2006-11-01 · 1 site observation
COMPLETED
Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous DetachmentNCT00198471 · 2005-07-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.